“Take” after LC16m8 for mpox

•LC16m8 is an attenuated live vaccine comprising attenuated vaccinia virus strains.•LC16m8 was approved in Japan for the prevention of mpox in August 2022.•A local reaction called “take” is observed after inoculation with LC16m8.

Saved in:
Bibliographic Details
Published in:International journal of infectious diseases 2023-09, Vol.134, p.290-291
Main Authors: Okumura, Nobumasa, Ishikane, Masahiro, Ujiie, Mugen, Ohmagari, Norio
Format: Article
Language:English
Subjects:
Antibodies, Viral
Humans
Mpox (monkeypox)
Smallpox
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•LC16m8 is an attenuated live vaccine comprising attenuated vaccinia virus strains.•LC16m8 was approved in Japan for the prevention of mpox in August 2022.•A local reaction called “take” is observed after inoculation with LC16m8.
ISSN:1201-9712
1878-3511
DOI:10.1016/j.ijid.2023.07.005